At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 211 enrolled
Drug / intervention
Ecnoglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of XW003 in Patients With T2DM Inadequately Controlled by Diet and Exercise Alone
In Brief
A Phase 3 clinical trial evaluating Ecnoglutide and Placebo for T2DM and Type 2 Diabetes Mellitus. Completed, enrolled 211 participants across 1 site.
Detailed Summary
The main purpose of this study is to investigate the efficacy and safety of XW003 versus placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled by diet and exercise alone
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsT2DM, Type 2 Diabetes Mellitus
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
Enrollment StartDec 2022
First PostedJan 2023
Primary CompletionJun 2024
Study CompletionOct 2024
TodayJul 2026
First PostedJan 11, 2023
Enrollment StartDec 29, 2022
Primary CompletionJun 12, 2024
Study CompletionOct 12, 2024
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 3.5 years ago
Interventions
Ecnoglutidedrug
Subcutaneous Injection
Placebodrug
Subcutaneous Injection with matched volume